SNBL announced the consolidated financial results for the fiscal year ended March 31, 2022 and supplementary information today.
For details, please check the links below:
SNBL announced the financial results for the third quarter ended December 31, 2021 and revisions to the full-year earnings and year-end dividend forecasts. For more details, please check the links below:
SNBL is pleased to announce that the English version of our Corporate Governance Report (Dec 2021) is now ready for stakeholders.
SNBL is pleased to announce that the English version of our Sustainability Report 2021 is now ready for stakeholders.
SNBL revised its earnings forecasts for the six months and full-year of the fiscal year ending March 31, 2022.
SNBL has established a Sustainable Developmental Goals (SDGs) committee.
Please see the link below for more details.
SNBL announced the results for the quarter ended June 30, 2021.
SNBL has announced their intention to participate in the development of a prophylactic DNA vaccine for SARS-CoV-2, the disease which causes COVID-19. The role of SNBL is to plan and conduct the preclinical safety studies of the DNA vaccine, which has collaboratively been developed by AnGes, Inc. and Osaka University, in order to conduct the clinical trial as early as possible. This vaccine uses plasmid DNA technology which means that it can be produced faster than attenuated vaccines. DNA vaccines are safe and work by inoculating a plasmid encoding the protein of the target pathogen.
SNBL's mission is to free patients from suffering, by supporting drug development and improving medical technology, and participation in this project gives SNBL the chance to do so for those suffering from the novel coronavirus.